Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177423 | 0.86 | GFER (0.72) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL4284871 | 0.85 | GFER (0.75) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL28003279 | 0.83 | GFER (0.68) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL2224601 | 0.83 | GFER (0.68) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL4902662 | 0.83 | LMNA (0.63) | TP53LMNAMAPTALDH1A1POLB | |
| SCHEMBL3369620 | 0.83 | LMNA (0.57) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL13064774 | 0.83 | GFER (0.68) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL3371889 | 0.83 | LMNA (0.56) | LMNAMAPTRAB9AALDH1A1HSD17B10 | |
| SCHEMBL3372943 | 0.83 | GFER (0.46) | GFERTP53LMNAMAPTRAB9A | |
| SCHEMBL4904228 | 0.82 | TP53 (0.49) | GFERTP53LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275502-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | claimed |
| US-20260034104-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-02-05 | — | — | US | disclosed |
| US-12440478-B2 | Process for preparing a potent thiazole compound, pharmaceutical formulation and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-10-14 | — | — | US | disclosed |
| US-20210275502-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| US-20210275502-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| CN-101080411-B | Thiazolopyridinone derivatives as MCH receptor antagonists | LILLY CO ELI | 2011-11-02 | — | — | CN | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| CN-101558075-A | 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists | LILLY CO ELI (US) | 2009-10-14 | — | — | CN | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-2089397-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| CN-101080411-A | Thiazolopyridinone derivatives as MCH receptor antagonists | LILLY CO ELI (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828207-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-4033977-A | ANTIINFLAMMATORY, ANTIDEPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440478-B2 | Process for preparing a potent thiazole compound, pharmaceutical formulation and uses thereof | TYR, MITF, TPP2 | GFER 3206/4885TP53 3240/4885LMNA 2729/4885 |
| US-20210275502-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | TYR, MITF, TPP2 | GFER 3206/4885TP53 3240/4885LMNA 2729/4885 |
| US-20260034104-A1 | PROCESS FOR PREPARING A POTENT THIAZOLE COMPOUND, PHARMACEUTICAL FORMULATION AND USES THEREOF | SSB, MITF, HLA-DRB1 | GFER 4530/4885TP53 1601/4885LMNA 553/4885 |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | GFER 3668/4885TP53 3759/4885LMNA 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.